Delayed in Medical Technology

Schering-Plough Announces Results of the Early ACS Trial

... Investigational Dosing is Not Superior to delayed Provisional Use in Patients with High-Risk Acute ... outcomes for patients with ACS compared to delayed provisional use. The primary efficacy endpoint ... angiography), compared with 10.0 percent of the delayed provisional group (p=0.23). At 30 days, the death ...

Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function

... referred to as DGFi) for prevention of delayed Graft Function (DGF) in patients undergoing ... of its capabilities in the RNAi arena." delayed graft function (DGF) is one of the most common ... (AKI) following major cardiac surgery and of delayed graft function in kidney transplantation. ...

Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed

... TAK-390MR combines dexlansoprazole with a Dual delayed Release(TM) (DDR) formulation, designed to ... Safety of TAK-390MR, a PPI with a Novel Dual delayed Release Formulation, in GERD Patients. ... Two Doses of TAK-390MR, a PPI with Novel Dual delayed Release Technology, as Maintenance Treatment for ...

Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS

... risk of developing MS over five years compared to delayed treatment." The study also demonstrated that ... PASAT score) compared to patients with delayed treatment (p= 0.0045).(1) PASAT, or the Paced ... of cognitive function compared to those with delayed treatment, which is good news for people with ...

GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)

... and vomiting, particularly in the delayed setting.(6) A new drug application for ... vs. 88 percent for control population) and delayed phases (86 percent in the single oral ... as the first 24 hours after chemotherapy, while delayed CINV is 24 hours to 120 hours following ....

Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center

... that single agent perifosine not only induced tumor regression and delayed tumor growth, but that perifosine also improved the survival of mice ... Memorial Sloan-Kettering Cancer Center, perifosine induced responses and delayed disease progression in adult patients with advanced brain tumors. ...

Quark Pharmaceuticals Presents at Asia TIDES Conference

... kidney injury (AKI) and a Phase I/II clinical study for the prophylaxis of delayed graft function (DGF) following renal transplantation. In addition to ... of acute kidney injury (AKI) following major cardiac surgery and of delayed graft function in kidney transplantation. For the structure of these ...

Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property

... activity towards RGCs. It significantly protected retinal neurons against delayed degeneration and reduced injury induced RGC death in vivo, the hallmarks ... trials via systemic delivery and DGFi with open IND for prevention of delayed graft function in kidney transplantation. Based on publicly available ...

Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy

... approval for its products, particularly Cloretazine(R) (VNP40101M), delayed or unfavorable results of drug trials, the possibility that favorable ... accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to ...

Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation

... and 106 to control in the 12-week study. Primary outcome measures were a delayed verbal memory task derived from the Wechsler Memory Scale-revised and the ... a statistically significant benefit in mild Alzheimer's patients on the delayed verbal memory task in the Souvenaid(TM) group, and also a significant ...

Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting

... approval for its products, particularly Cloretazine(R) (VNP40101M), delayed or unfavorable results of drug trials, the possibility that favorable ... accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to ...

Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting

... approval for its products, particularly Cloretazine(R) (VNP40101M), delayed or unfavorable results of drug trials, the possibility that favorable ... accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to ...

Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting

... approval for its products, particularly Cloretazine(R) (VNP40101M), delayed or unfavorable results of drug trials, the possibility that favorable ... accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to ...

TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis

... TAK-390MR, the first proton pump inhibitor (PPI) with an innovative dual delayed release technology, in healing patients with erosive esophagitis (EE) and ... Disease Week (DDW) annual meeting in San Diego. "The innovative dual delayed release technology delivers TAK-390MR in two separate releases, which is a ...

Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine

... approval for its products, particularly Cloretazine(R) (VNP40101M), delayed or unfavorable results of drug trials, the possibility that favorable ... accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to ...

Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML

... Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable ... accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to ...

Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting

... Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable ... accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to ...

Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation

... Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable ... accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to ...

Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors

... Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable ... accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty ...

Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression

... compared Betaseron treatment initiated after a first clinical event with delayed treatment. The study was conducted at 98 sites in 20 countries and ... with Betaseron to prospectively assess the impact of such early versus delayed treatment with Betaseron on the long-term course of the disease for a ...

Tapestry Reports Second Quarter 2007 Results

... and other factors include risks that clinical trials for TPI 287 will be delayed due to institutional approvals, patient recruitment, formulation and ... and enforce our own intellectual property; that development of TPI 287 is delayed or terminated because the costs of further development exceed its value; ...

Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML

... Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable ... accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty ...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

... and efficacy findings; (ii) the timing or success of the commencement or end of clinical trials and commercial launch of partnered products may be delayed or unsuccessful due to slower than anticipated patient enrollment, drug manufacturing challenges, changing standards of care, clinical trial design, ...

Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

... was superior to placebo in improving positive and negative syndrome scale (PANSS) total scores in the acute treatment trials and significantly delayed time to relapse vs. placebo in the longer-term maintenance study. The most recent acute symptom control study was a multi-center, randomized, ...

Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study

... New Drug Application (NDA) filings, not being submitted in a timely manner; regulatory approval, including approval for exenatide once weekly, being delayed or not received; or manufacturing and supply issues. The potential for exenatide once weekly may also be affected by government and commercial ...

New Heart Ultrasound Research Reveals Life-Saving Treatment Alternatives and Advancements for Heart Patients

... symptoms of aortic stenosis are not being identified or are not attributed to aortic stenosis. As a result, surgery in these patients is frequently delayed or not performed," said Dr. Benjamin H. Freed of the University of Chicago Medical Center, a lead author of the study. Patients with suspected ...

Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009

... filings, including the NDA filing mentioned in this press release, not being submitted and/or accepted in a timely manner; regulatory approval being delayed or not received; or manufacturing and supply issues. The potential for BYETTA and/or exenatide once weekly may also be affected by government and ...

RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder

... 19 /PRNewswire/ -- New data demonstrate that maintenance therapy with RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment (RLAT) significantly delayed the time to relapse compared to placebo in patients with Bipolar I Disorder. Results of the study were presented this week at a major medical ....

Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever

... regulatory submissions, manufacturing and other important aspects of the Acetavance development program, and the risk that regulatory approval may be delayed if their performance is found to have been substandard; risks associated with FDA heightened scrutiny over the new drug approval process and the ...

Melanoma and Pregnancy: What Every Woman Needs to Know About the Risks, Prognosis

... the same treatment as any other person -- mainly a wide local excision to remove the tumor. Dr. Driscoll explained that this procedure should not be delayed and can be safely performed under local anesthesia during pregnancy. In cases where a wide local excision must be performed in a later stage of ...

MedNet Solutions Certified to Score SF-12v2 Health Survey

... miscues are a few of the common errors in administering PROs during clinical trials. These kinds of errors have cost companies millions and delayed the introduction of new treatments. While PROs are powerful tools that provide valuable and necessary clinical trial data, simple formatting errors ...

Study Confirms: Your Hidden Food Allergies Are Making You Fat

... sensitivities, are unique to each individual and can cause inflammatory diseases, and an inability to lose weight. Food sensitivities often provoke delayed and chronic symptoms, like IBS, migraine and arthritis, that are not as obvious as the dramatic and immediate onset of "true" food allergies, such as ...

Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study

... Drug Application (NDA) filings, including the NDA filing for exenatide once weekly, not being submitted in a timely manner; regulatory approval being delayed or not received; or manufacturing and supply issues. The potential for exenatide once weekly may also be affected by government and commercial ...

Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.

... proceed in the United States. Nor can there be any assurance that the planned dose escalation studies in Switzerland or any other country will not be delayed by regulators there or that those studies, when conducted, will be successful or provide data acceptable to the FDA. Additional information ...

IBT Laboratories to Launch New Pneumococcal Antibody Avidity Test at AAAAI Meeting, Booth 729

... with this mutation may benefit from targeted therapy. The new T-Cell Rx(TM) test assists physicians in assessing patients who have experienced a delayed drug reaction. IBT will present two scientific posters at the conference: Saturday, 9:45-10:45 am - # 41: T Cell Immunity ...

Neuralstem's Human Stem Cells Integrate into Nervous System of Rats with Animal Model of ALS

... said Dr. Karl Johe, Neuralstem's Chief Scientific Officer and a study co-author. "Our earlier work with this ALS model showed that the stem cells delayed onset of the disease and played a neuroprotective role. Now we have clear evidence that they can become an integral part of the rat nervous system ...

Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)

... efficacy, safety or other factors; (ii) the timing or success of the commencement or end of clinical trials and commercial launch of new drugs may be delayed or unsuccessful due to regulatory delays, clinical trial design, slower than anticipated patient enrollment, drug manufacturing challenges, changing ...

American Academy Of Orthopaedic Surgeons 2009 Annual Meeting 'Highlights and Hot Topics'

... Bone and Soft Tissue Health 6.2 million bone fractures occur annually in the United States and as many as 10% of these fractures show delayed healing or do not heal completely. Recently research has focused on solving this medical problem through biologically based medications, and a ...

ACRO Comments on NEJM Article on Globalization of Clinical Research

... According to the non-profit Center for Information & Study on Clinical Research Participation, 80% of clinical trials in the United States are delayed at least one month because of unfulfilled enrolment. The ramifications of this limited participation are clear. According to the National Cancer ...

Preterm Births Rise 36 Percent Since Early 1980s

... and even late preterm infants have a greater risk of breathing problems, feeding difficulties, temperature instability (hypothermia), jaundice, delayed brain development and an increased risk of cerebral palsy and mental retardation. Last month, the March of Dimes issued its first-ever Premature ...